Apple Inc. (AAPL · NASDAQ)
AAPL · MARKET VIEW
Market view · as of Oct 14, 2026
Revenue (TTM)
$466.82B
+16.4% YoY
Gross margin
48.7%
EPS (latest q)
$2.02
vs $1.88 est · beat
52-wk position
100.0%
0.0% vs 52w high · +3.0% 1mo
Price (last ~year)
Apple (AAPL) sits at all-time highs, closing at $341.27 with a $4.98T market cap, up 4.6% over three months and trading 17.2% above its 200-day SMA. The company has beaten earnings estimates in all four of its last quarters, most recently reporting $2.02 versus $1.88 expected, while trailing-twelve-month revenue reached $466.82B with 16.4% YoY growth and 28.7% earnings growth. Margins remain strong at 48.7% gross and 32.6% operating, with quarterly free cash flow of $31.91B against modest leverage of 0.5x debt/EBITDA. Valuation is elevated at a 39.1 P/E and 2.706 PEG, though the analyst target of $328.61 sits below the current price.
Valuation
- Market cap
- $4.98T
- P/E
- 39.1
- PEG
- 2.706
- P/B
- 45.74
- P/S
- 10.73
- EV/EBITDA
- 29.41
- Beta
- 1.069
- Analyst target
- $328.61
Quality & returns
- Gross margin
- 48.7%
- Operating margin
- 32.6%
- Profit margin
- 27.6%
- ROE
- 148.8%
- ROA
- 27.1%
Price movement
- Last
- $341.27
- 1-month
- +3.0%
- 3-month
- +4.6%
- RSI (14)
- 55
- vs SMA200
- +17.2%
- 52-wk position
- 100.0% 0.0% vs high
Quarterly trajectory
Revenue by quarter (oldest → newest)
| Quarter | Revenue | Op income | Net income | EBITDA |
|---|---|---|---|---|
| 2026-06-30 | $109.42B | $35.70B | $29.79B | $39.02B |
| 2026-03-31 | $111.18B | $35.88B | $29.58B | $39.32B |
| 2025-12-31 | $143.76B | $50.85B | $42.10B | $54.22B |
| 2025-09-30 | $102.47B | $32.43B | $27.47B | $35.55B |
Recent news
- Neutral Apple Stock Hits All-Time Highs — And There Could Be Good News About iPhone Duo · 2026-10-13
- Bullish Apple debuts new smart home devices, partner-developed hardware · 2026-10-13
- Neutral Strive Announces Proposed Initial Public Offering of SATS Stock · 2026-10-13
- Somewhat-Bullish Nurix Therapeutics, Inc. (NRIX) Reports Q3 EPS of $4.73 · 2026-10-13
- Neutral Form SCHEDULE 13G/A Lantern Pharma Inc. Filed by: Empery Asset Management, LP · 2026-10-13
- Neutral Form S-8 JX Luxventure Group Inc. · 2026-10-13
Sources this view read
- fundamentals Company overview & valuation (Alpha Vantage OVERVIEW)
- filing Quarterly financial statements (Alpha Vantage INCOME/BALANCE/CASH)
- earnings Reported earnings history (Alpha Vantage EARNINGS)
- prices Adjusted daily prices (Alpha Vantage TIME_SERIES_DAILY_ADJUSTED)